To treat the coagulopa-
H
emorrhage remains the most common preventable cause of combat death. 1 Upon autopsy review, 80% to 85% of deaths in combat are classified as nonsurvivable as the result of devastating injury. 1, 2 Of the remaining 15% to 20% of survivable deaths, 66% to 80% of patients die from hemorrhage. 1, 2 Severe trauma, defined as an Injury Severity Score (ISS) of greater than 15, 3 is common during combat, representing 20% of all trauma admissions at one U.S. Army combat support hospital in Baghdad in 2004. 4 Recent combat operations in the Middle East have refocused attention on the early coagulopathy of trauma present on hospital admission. [5] [6] [7] Trauma and shock severity correlate with the degree of coagulopathy, [6] [7] [8] [9] which in turn has been associated with mortality. The most severely injured 10% of patients 10 may require massive transfusion, defined as the transfusion of 10 or more red blood cell (RBC) units in a 24-hour period. [11] [12] [13] In civilian trauma centers, the incidence of patients with traumatic injuries requiring massive transfusion ranges between 1% and 3%, with an incidence of massive transfusion reported as high as 15% in patients with the most severe injuries. 5, 16 The majority of massive transfusion patients die within 6 to 12 hours of hospital arrival, 4, 17, 18 mortality rates for patients requiring massive transfusion range between 20% and 50%, 11, 16, 19 and massive transfusion has been shown to be independently associated with increased mortality. 14 The high mortality risk in massive transfusion patients largely results from the well-described "lethal triad" characterized by hypothermia, acidosis, and coagulopathy. 20 -23 Damage control resuscitation addresses that lethal triad immediately at admission to the combat hospital or civilian trauma center. 10 Intravascular volume resuscitation is accomplished using thawed human plasma as primary resuscitation fluid in a 1:1 or 1:2 ratio with RBCs. 5,11,24 -27 For patients who require continued resuscitation, a massive transfusion protocol is activated and the blood bank delivers an additional 6 units of RBCs, 6 packs of platelets, 6 units of plasma, and one 10-unit bag of cryoprecipitate to the operating room. 10 Cryoprecipitate is a human blood product derived from the precipitate fraction of cold-thawed human plasma. 28 It typically contains about 2.5 g of fibrinogen per 10-unit bag. Among all clotting factors in human plasma, fibrinogen is the first to decrease to pathophysiologic levels in hypocoagulable patients who have undergone major elective abdominal surgery with blood loss exceeding 20% of their calculated blood volume. 29 This hypofibrinogenemia does not seem to be completely explained by blood loss and resuscitation alone. 30, 31 After moderate hemorrhagic shock in pigs, we reported that fibrinogen decreases as a result of constant production and increased consumption and hyperfibrinolysis, which results in prolonged blood clotting times. 32, 33 Additionally, fibrinogen replacement has been shown to restore normal coagulation times in both coagulopathic pigs in hemorrhagic shock 34 and in diluted coagulopathic in vitro human blood. 35 Our hypothesis was that early administration of fibrinogen to patients with severe injuries requiring a massive transfusion would decrease death from hemorrhage as a result of minimizing coagulopathy, excessive bleeding, and shock. Our objective in this retrospective study was to determine whether an increased ratio of fibrinogen to RBCs transfused would improve survival to hospital discharge in patients with severe traumatic injuries requiring massive transfusion at a combat support hospital by decreasing death from hemorrhage. 36 The JTTR was queried for patients who received a massive transfusion, defined as 10 or more RBC units [including both RBCs and fresh whole blood (FWB) units] within a 24-hour period, between January 2004 to October 2005. Data analyzed from the JTTR in this study were age, combined ISS, recombinant Factor VIIa use, overall mortality at hospital discharge, mortality resulting from hemorrhage, and laboratory values and vital signs at admission to the combat support hospital (temperature, systolic blood pressure, hemoglobin, platelet level, international normalized ratio [INR] , and base deficit) as well as the number in units and type of blood products administered within 24 hours of hospital admission. Numbers of units of blood products tabulated were packed red blood cell (RBC) units, fresh whole blood (FWB) units, fresh frozen plasma (FFP) units, cryoprecipitate (Cryo) 10-unit bags, and apheresis platelet (aPLT) units. Fibrinogen levels on hospital admission were not available in theater.
PATIENTS AND METHODS
We calculated the F:R ratio ( Fig. 1 ) according to standard amounts of fibrinogen contained in each blood component (Table 1 ). In the numerator of the ratio, each blood product is multiplied by a conversion factor that converts the units of that blood product transfused to grams of fibrinogen in that blood product (Fig. 1) . Note that cryoprecipitate contains 2.5 g of fibrinogen per 10-unit bag, and FWB contains To analyze the effect of fibrinogen-to-red cell (F:R) ratios on mortality, patients were initially divided into eight ratio groups ( Fig. 2A) and then into quartiles (Fig. 2B ) based on the ratio of F:R units transfused. The first quartile consisted of patients with F:R ratios of 0 to Յ0.2 g/unit, the second 0.2 to Յ0.4 g/unit, the third 0.4 to Յ0.6 g/unit, and the fourth Ն0.6 g/unit. A sharp drop in mortality was noted at 0.2 g/unit between the first and second quartile, so the four ratio groups were combined into two groups, with a low F:R ratio of Ͻ0.2 g/unit and a high F:R ratio of Ն0.2 g/unit. We then plotted both mortality and death resulting from hemorrhage as a function of low F:R ratio (Ͻ0.2 g/unit) and high F:R ratio (Ն0.2 g/unit; Fig. 3 ).
All continuous parametric data are described as mean (ϮSD). Comparisons were performed with Student's t test for continuous data and with Fisher's exact test for categorical data. Statistical analysis was performed with SPSS 14.0 (Chicago, IL). Significant differences were determined at p Ͻ 0.05. A logistic regression model was developed using multivariate logistic regression analysis to determine which sets of variables were independent predictors of mortality. Correlation analysis was performed using both Pearson's and Spearman's correlation analysis with mortality as the dependent correlation factor. Values with greater than 0.15 correlation coefficients were considered candidates for model development. Regression analysis was performed using a backward likelihood ratio logistic regression. Results were validated using a forward stepwise regression 
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RESULTS
During the 22-month period between January 2004 and October 2005, the combat support hospital received 5,586 patients from both military and civilian populations with traumatic injuries. The JTTR identified 252 of those 5,586 casualties (4.5%) who required massive transfusions. The mean age of the patients studied was 26 (Ϯ7.5) years. The mean ISS was 21 (Ϯ9.8). The overall mortality was 30% (75 of 252). The mean (SD) F:R ratios transfused for the low and high groups were 0.1 g/unit (Ϯ0.06) and 0.48 g/unit (Ϯ0.2), respectively ( p Ͻ 0.001). Mortality was 27 of 52 (52%) and 48 of 200 (24%) in the low and high F:R ratio groups, respectively ( p Ͻ 0.001; Fig. 3 ). The incidence of death from hemorrhage was higher in the low F:R group, 23 of 27 (85%), compared with the high F:R group, 21 of 48 (44%) ( p Ͻ 0.001; Table 2 ). Additional comparisons of variables between patients in the low F:R ratio (Ͻ0.2 g/unit) and the high F:R ratio (Ն0.2 g/unit) groups are summarized in Table 2 . Upon multiple logistic regression, base deficit, ISS, and high F:R ratio (Ն0.2 g fibrinogen per red cell unit [RBC or FWB] transfused) were noted to be independently associated with survival (Table 3) .
Correlation analysis of variables resulted in eight variables as candidates for further multivariate analysis. These included hemoglobin, platelets, INR, base deficit, FFP, ISS, F:R ratio (continuous), and F:R ratio (high/low). The F:R ratio (high/low) variable had a higher correlation coefficient than F:R ratio (continuous) variable (Ϫ0.247 vs. Ϫ0.178) and was, therefore, chosen for multivariate analysis over the continuous F:R ratio variable. The INR variable showed a significant positive correlation (0.290) to mortality, but was excluded for low sample size (168 of 252). Recombinant Factor VIIa use was not correlated with mortality in this analysis and was therefore not a candidate for multivariate logistic regression.
Backward and forward regression analysis resulted in the base deficit, ISS, and F:R ratio (high/low), as the best predictors of mortality with a receiver operating characteristic curve area of 0.71 (95% confidence interval 0.63-0.79; Fig.  4 and Table 3 ). Hosmer and Lemeshow tests showed a good model fit with a 2 of 3.17 ( p ϭ 0.92). The model correctly predicted 93% (10 of 147) of survivors and 29% (17 of 50) of deaths in the sample set using a 0.5 predictive positive cutoff. Mortality rate predicted increased to 56% (33 of 59) using a 0.3 positive cutoff value (survival rate decreased to 76%, correct predictions were obtained in 36 of 147).
DISCUSSION
Previous studies have shown that fibrinogen levels fall early in elective surgical patients with significant blood loss, 29 and in pigs 32, 33 subjected to blood loss, but neither blood loss nor resuscitation 30, 31 completely explains this decrease in fibrinogen levels. Acidosis in a swine model caused INR indicates international normalized ratio; F:R ratio, fibrinogen-to-red cell ratio; NS, no significant difference; both group percentages equal.
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a near twofold increase in fibrinogen degradation but no changes in fibrinogen synthesis. 37 Furthermore, neither bicarbonate 38 nor tris-hydroxymethyl-aminomethane 39 pH neutralization in similar swine models immediately corrected an acidosis-induced coagulopathy. On the other hand, replenishment of fibrinogen restored normal coagulation times in coagulopathic pigs in hemorrhagic shock 34 and in diluted coagulopathic in vitro human blood. 35 Our results are consistent with the studies above in that they demonstrate that an increased amount of fibrinogen in relation to the amount of RBCs transfused was independently associated with survival in combat casualties requiring massive transfusions. This is important since the majority of preventable deaths in combat are due to hemorrhage and strategies that can decrease death from hemorrhage in combat will significantly impact survival in this population. To the best of our knowledge, this is the first article to demonstrate the association of high levels of transfused fibrinogen on the survival of casualties requiring massive transfusion.
High concentrations of fibrinogen are available not only from cryoprecipitate but also from plasma-derived fibrinogen concentrates. Fibrinogen is also now being produced using recombinant techniques and is available in a lyophilized powder form (Pharming Group, Leiden, The Netherlands). The ability to reconstitute recombinant fibrinogen from a lyophilized powder form surmounts the logistical hurdle that burdens FFP administration in military operations, i.e., the need to transport frozen human plasma thousands of miles from home station to military hospitals in the combat zone. Future trials comparing equal amounts of fibrinogen in FFP, cryoprecipitate, and fibrinogen concentrates for coagulopathic patients are needed.
Recombinant Factor VIIa (NovoSeven, NovoNordisk, Princeton, NJ) is another clotting factor available in lyophilized powder form that many trauma centers have recently integrated into their massive transfusion protocols. Recombinant Factor VIIa reduces the total number of red cell units transfused in combat casualties, 36 decreases death in combat casualties requiring massive transfusion, 4 and requires adequate levels of platelets and fibrinogen in place to achieve hemostasis. 40, 41 Administering recombinant Factor VIIa in the face of low fibrinogen levels may not produce the desired hemostatic effect; in addition, acidosis should be reversed and platelet deficiencies corrected either simultaneously with or before recombinant Factor VIIa administration. 41 Although our data reveal a strong association between a high F:R transfusion ratio and survival, that association does not necessarily imply causation. During the data collection period from January 2004 through October 2005, platelet availability varied, and deployed U.S. military medical personnel shifted progressively away from crystalloid toward more plasma and whole blood in factor-specific targeted resuscitation of combat casualties. Progressively smaller amounts of crystalloid infused may also have contributed to these results. 42, 43 Although compelling, our results are limited by the fact that fibrinogen was administered as cryoprecipitate, plasma, platelets, and whole blood, with each product containing other coagulation factors in varying amounts. Could those nonfibrinogen clotting factors-especially in plasma, because 239 of 252 casualties in our study received plasma-be responsible for the lowered mortality seen in the high F:R ratio group? Unfortunately, our sample size of 252 massive transfusion patients is not large enough to make valid comparisons between fibrinogen sources: plasma, cryoprecipitate, whole blood, etc., or to ascertain precisely where the mortality benefit came from: fibrinogen or from fibrinogen in addition to other clotting factors. A prospective randomized trial on massive transfusion casualties using cryoprecipitate, plasma, platelets, and whole blood as sole fibrinogen sources in separate treatment arms would come closer to answering that question; the likelihood of such a trial being conducted, however, may be remote for ethical reasons.
CONCLUSION
Although the sample size in this study is small, our data demonstrate that transfusion of a high F:R ratio (Ն0.2 g of fibrinogen per red cell unit transfused) was independently associated with survival to hospital discharge, primarily by decreasing death from hemorrhage. One 15-mL cryoprecipitate bag containing 250 mg of fibrinogen can be transfused per unit of RBCs to achieve this ratio; plasma and whole blood seem to be just as capable of supplying the needed fibrinogen. Clinicians can meet this requirement by (1) transfusing 1 unit of FFP for every 2 units of red cells transfused, or (2) transfusing 1 unit of whole blood for every 4 units of red cells transfused (Table 1) 
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Volume 64 • Number 2 S83 bag of cryoprecipitate for every 10 units of red cells transfused. Whether the survival benefit of the increased F:R ratio is a result of fibrinogen alone or to fibrinogen working with the other clotting factors present in plasma and whole blood is unknown. More prospective studies are needed to evaluate the best source of fibrinogen and the optimal empiric ratio of fibrinogen to RBCs in patients requiring massive transfusion.
